UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 18, 2024
BIOCARDIA, INC. |
| (Exact name of registrant as specified in its charter) |
Delaware | | 001-38999 | | 23-2753988 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
320 Soquel Way
Sunnyvale, California 94085 | |
| (Address of principal executive offices and zip code) | |
Registrant’s telephone number, including area code: (650) 226-0120
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.001 | BCDA | The Nasdaq Capital Market |
| |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter) ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |
| |
Item 8.01 Other Events.
On September 18, 2024, BioCardia, Inc. (the “Company”) issued a press release announcing that is has received formal written notice from The Nasdaq Stock Market, LLC’s office of General Counsel (“Nasdaq”) that the Company has demonstrated compliance with Listing Rule 5550(b)(1) (the “Equity Rule”) of the Nasdaq Stock Market, as required by the Hearings Panel’s (“Panel”) decision dated May 13, 2024. Accordingly, the Panel has determined to continue the listing of the Company’s securities on The Nasdaq Stock Market and is closing this matter. The Company understands that Nasdaq will continue to monitor Company’s ongoing compliance with The Nasdaq Stock Market’s continued listing requirements.
A copy of the press release is attached as Exhibit 99.1 to the current report on Form 8-K.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits |
Exhibit Number | | Description |
| | | |
| 99.1 | | |
| 104 | | Cover Page Interactive Data File (embedded within the Inline XBRL Document. |
| |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BIOCARDIA, INC. | |
| | |
| /s/ Peter Altman, Ph.D. | |
| Peter Altman, Ph.D. | |
| President and Chief Executive Officer | |
| | |
| Date: September 18, 2024 | |
